Agilis Biotherapeutics, Inc. — Form D
Agilis Biotherapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2017-02-24. The offering totals $23.3M, of which $12.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-02-24
- Form: D
- Accession: 0001595971-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $23.3M
- Amount sold: $12.7M
- Remaining: $10.7M
- Investors: 19
- Date of first sale: 2017-02-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-281302
Issuer
- Name: Agilis Biotherapeutics, Inc.
- CIK: 0001595971
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 245 FIRST STREET, CAMBRIDGE, MA, 02142
- Phone: (617)444-8706
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| G. Houston Hall | Director | Cambridge, MA |
| Robert J Hardie | Director | Cambridge, MA |
| Mark J Pykett | Director | Cambridge, MA |
| Ian J Ratcliffe | Director | Cambridge, MA |
| Alexander M Seaver | Director | Cambridge, MA |
| Adrian Z Stecyk | Director | Cambridge, MA |
| Mark J Pykett | Executive Officer | Cambridge, MA |
| Alexander M Seaver | Executive Officer | Cambridge, MA |
| Adrian Z Stecyk | Executive Officer | Cambridge, MA |
| G. Houston Hall | Executive Officer | Cambridge, MA |
| Arthur J Tzianabos | Director | Cambridge, MA |
Other filings by this issuer (2)
More